^
Chr del(11q)
Chronic Lymphocytic Leukemia
zanubrutinib
Sensitive
:
B
SOHO 2022 - 1 week - (New B)
CD20 expression
B Acute Lymphoblastic Leukemia
rituximab
Sensitive
:
C3
SOHO 2022 - 1 week - (New C3)
IDH1 mutation
Acute Myelogenous Leukemia
MEN1703
Sensitive
:
C3
SOHO 2022 - 1 week - (New C3)
KAT6A-CREBBP fusion + FLT3-TKD mutation
Acute Myelogenous Leukemia
cytarabine + midostaurin + daunorubicin
Sensitive
:
C4
SOHO 2022 - 1 week - (New C4)
FLT3-ITD mutation
Acute Myelogenous Leukemia
TP-0184
Sensitive
:
D
SOHO 2022 - 1 week - (New D)
BRAF V600E
Hairy Cell Leukemia
trametinib + dabrafenib
Sensitive
:
C3
Blood - 2 weeks - (New C3)
CD20 positive
Chronic Lymphocytic Leukemia
rituximab-abbs
Sensitive
:
A1
FLT3 mutation
Acute Myelogenous Leukemia
gilteritinib
Sensitive
:
A1
IDH2 mutation
Acute Myelogenous Leukemia
enasidenib
Sensitive
:
A1
No biomarker
Acute Myelogenous Leukemia
glasdegib
Sensitive
:
A1
No biomarker
B Acute Lymphoblastic Leukemia
tisagenlecleucel-T
Sensitive
:
A1
No biomarker
Childhood B Acute Lymphoblastic Leukemia
tisagenlecleucel-T
Sensitive
:
A1
No biomarker
Chronic Lymphocytic Leukemia
rituximab + ibrutinib
Sensitive
:
A1
No biomarker
Acute Myelogenous Leukemia
azacitidine oral
Sensitive
:
A1
No biomarker
Acute Myelogenous Leukemia
cytarabine / daunorubicin liposomal formulation
Sensitive
:
A1
Chr del(17p)
Chronic Lymphocytic Leukemia
venetoclax + obinutuzumab
Sensitive
:
A1
TP53 mutation
Chronic Lymphocytic Leukemia
venetoclax + obinutuzumab
Sensitive
:
A1
No biomarker
Chronic Lymphocytic Leukemia
venetoclax + obinutuzumab
Sensitive
:
A1
BCR-ABL1 fusion
Chronic Myeloid Leukemia
dasatinib
Sensitive
:
A1
BCR-ABL1 T315I
Chronic Myeloid Leukemia
asciminib
Sensitive
:
A1
No biomarker
Chronic Lymphocytic Leukemia
orelabrutinib
Sensitive
:
A1
FLT3 mutation
Acute Myelogenous Leukemia
midostaurin
Sensitive
:
A1
CD33 positive
Acute Myelogenous Leukemia
gemtuzumab ozogamicin
Sensitive
:
A1
BCR-ABL1 fusion
Acute Lymphocytic Leukemia
imatinib
Sensitive
:
A1
No biomarker
Chronic Myeloid Leukemia
omacetaxine mepesuccinate
Sensitive
:
A1
CD22 positive
B Acute Lymphoblastic Leukemia
inotuzumab ozogamicin
Sensitive
:
A1
BCR-ABL1 fusion
B Acute Lymphoblastic Leukemia
inotuzumab ozogamicin
Sensitive
:
A1
CD20 expression
Chronic Lymphocytic Leukemia
rituximab-arrx
Sensitive
:
A1
BCR-ABL1 T315I
Chronic Myeloid Leukemia
ponatinib
Sensitive
:
A1
BCR-ABL1 T315I
Acute Lymphocytic Leukemia
ponatinib
Sensitive
:
A1
No biomarker
Acute Lymphocytic Leukemia
blinatumomab
Sensitive
:
A1
No biomarker
B Acute Lymphoblastic Leukemia
blinatumomab
Sensitive
:
A1
No biomarker
Acute Myelogenous Leukemia
venetoclax
Sensitive
:
A1
No biomarker
Chronic Myeloid Leukemia
ponatinib
Sensitive
:
A1
TP53 mutation
Chronic Lymphocytic Leukemia
venetoclax
Sensitive
:
A1
No biomarker
Chronic Lymphocytic Leukemia
rituximab-abbs
Sensitive
:
A1
No biomarker
Chronic Lymphocytic Leukemia
Rixathon (rituximab biosimilar)
Sensitive
:
A1
No biomarker
Chronic Lymphocytic Leukemia
rituximab-pvvr
Sensitive
:
A1